Related Experiment Video

Updated: Jun 16, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants

Simon Rückinger1, Mark van der Linden, Rüdiger von Kries

  • 1Division of Epidemiology, Ludwig-Maximilians-University of Munich, Institute of Social Pediatrics and Adolescent Medicine, Germany. simon.rueckinger@med.uni-muenchen.de

BMC Infectious Diseases
|January 21, 2010
PubMed

Insights

7-valent pneumococcal conjugate vaccination (PCV7) effectively protects preterm infants from invasive pneumococcal disease (IPD). This study shows PCV7 significantly reduced IPD rates in preterm infants, supporting timely vaccination.

Area of Science:

  • Pediatrics
  • Immunology
  • Public Health

Background:

  • Limited data exists on the effectiveness of 7-valent pneumococcal conjugate vaccination (PCV7) in protecting preterm infants from invasive pneumococcal disease (IPD).
  • Previous randomized trials involved small numbers of preterm infants, necessitating further evidence.

Purpose of the Study:

  • To evaluate the impact of PCV7 on invasive pneumococcal disease (IPD) rates in preterm infants in Germany.
  • To compare IPD occurrence in preterm and general infant populations before and after PCV7 introduction.

Main Methods:

  • Active, prospective surveillance of IPD in children in Germany.
  • Comparison of IPD incidence in preterm and all infants born in 2000 versus 2007.

Main Results:

  • A significant reduction in IPD rates was observed in the overall infant population (15.0 to 8.5 per 100,000).
  • A comparable reduction in IPD notification rates was seen in preterm infants (26.1 to 16.7 per 100,000).
  • Preterm infants diagnosed with IPD were largely unvaccinated or incompletely vaccinated.

Conclusions:

  • PCV7 demonstrates effective protection for preterm infants against IPD.
  • Recommendations support vaccinating preterm infants according to their chronological age.
Abstract

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...